Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bank of Cyprus, John Menzies swing to interim profit

Wed, 01st Sep 2021 12:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Bank of Cyprus Holdings PLC - Strovolos, Cyprus-based financial services company - For the first half of 2021, swings to pretax profit of EUR2.1 million from loss of EUR124.9 million, due to narrowed credit losses to cover risk on loans and advances at EUR48.3 million from EUR183.7 million. Net interest income dropped 9.3% to EUR152.2 million from EUR167.8 million, however turnover grew 3.9% year-on-year to EUR391.4 million from EUR376.7 million. Declared no dividends during the period.

----------

John Menzies PLC - Edinburgh-based aviation services provider - For the first half of 2021, swings to pretax profit of GBP4.7 million from a loss of GBP80.1 million a year before, driven by the lack of several one-off costs, including restructuring charges and asset impairment costs. However, revenue declined 3.6% year-on-year to GBP415.8 million from GBP431.5 million, as travel restrictions lead to a reduction in passenger flights, hurting the group's ground and fuelling services businesses. Looking ahead, ground services and fuelling volumes remain subdued and are not expected to return to pre-pandemic levels before 2023. Declares no interim dividend, in line with year before.

----------

Kropz PLC - phosphate explorer with assets in South Africa and Republic of Congo - For the six months ended June, pretax loss narrows to USD7.4 million from USD14.7 million the year before, due to lower finance costs from lower foreign exchange losses. During the period, further progress at Elandsfontein has been made, however minor setbacks have caused the target date for commissioning to be pushed later into the fourth quarter of 2021. Funding shortfall of USD8.5 million is expected before first revenue from rock sales is expected in the first quarter of 2022.

----------

SEC Newgate SpA - Italian strategic communications and advocacy firm - For the first half of 2021, pretax profit rose 53% to EUR2.3 million from EUR1.5 million due to improved profitability while revenue grew 15% to EUR36.3 million from EUR31.5 million, on a stronger performance from Advocacy & Public Affairs and Integrated Services.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - For the year ended June 30, posts pretax loss of USD13.5 million, narrowed from USD18.8 million, driven by the lack of a USD5.1 million impairment charge on intangible assets. In addition, revenue rose 43% to USD3.0 million from USD2.1 million, driven by strong phytocannabanoid sales amounting to around USD2.0 million. Looking ahead, expects significant growth in the coming year, both in the sales of its existing products and in its clinical pipeline.

----------

Johnson Service Group PLC - Cheshire, England-based textile rentals - For the six months ended June 30, pretax loss narrows to GBP14.0 million from GBP18.6 million, as a result of lower costs and a reduction in bank debt, despite revenue which declined 13% year-on-year to GBP99.6 million from GBP114.8 million, as the Hotel, Restaurant & Catering Business division is severely affected by the lockdown at the start of 2021. However, volumes started to increase from April onwards. Declares no dividend for the period, in line with the year before. Looking ahead, expects annual results to meet the higher end of market expectations.

----------

Uniphar PLC - Dublin-based healthcare services firm - For the first half of 2021, posts pretax profit of EUR20.7 million, up 31% from EUR15.8 million the prior year, on revenue which grew 11% year-on-year to EUR964.9 million from EUR871.3 million, driven by strong performances in the Commercial & Clinical and Supply Chain & Retail divisions on client growth and the acquisition of 36 Hickey's retail pharmacies. Gross profit rises 31% to EUR134.3 million from EUR102.6 million. Looking ahead expects a rise in gross profit from all segments for 2021 as a whole, while M&A will remain an important part of Uniphar's strategy.

----------

Churchill China PLC - Stoke-On-Trent, England-based ceramic products for hospitality and retail markets - For the six months ended June 30, swings to pretax profit of GBP977,000 from a loss of GBP382,000 the year before, on revenue which grew 27% year-on-year to GBP23.9 million from GBP18.9 million, driven by a strong increase in order levels in May and June as lockdown restrictions were lifted. Restores interim dividend payout at 6.7 pence per share. Looking ahead, continues to trade in line with management expectations and is confident in meeting its business and financial targets both short and long term.

----------

Arcontech Group PLC - real-time financial market data product and service provider - For the year ended June 30, pretax profit remained flat at GBP1.4 million, in spite of revenue rising 1.1% year-on-year to GBP2.99 million from GBP2.96 billion on increased sales despite a level of caution seen from customers. Raises final dividend by 10% to 2.75 pence per share from 2.50p a year prior. Looking ahead, due to the impact of Covid-19 on net sales, annual profit for the current financial year is expected to be flat or lower, with a pick up in revenue not expected until the 2023 financial year.

----------

KRM22 PLC - risk management company - For the first half of 2021, pretax loss widens to GBP1.7 million from GBP1.2 million a year before, due to higher administrative costs and a decline in revenue to GBP2.2 million from GBP2.3 million, driven by a decline in recurring revenue on delays in signing certain contracts, as well as the loss of two customers.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.